18C2.8.3細胞 
	
		數量:	大量
	
	
		ATCC Number:	HB-9571?
	
	
		運輸方式:	凍存運輸
	
	
		生長狀態:	懸浮生長
	
	
		細胞形態:	**樣
	
	
		是否是腫瘤細胞:	0
	
	
		物種來源:	小鼠
	
	
		Designations:	18C2.8.3
	
	
		18C2.8.3細胞Depositors:	 Univ. Georgia Res. Fndn.
	
	
		Biosafety Level:	1
	
	
		Shipped:	frozen
	
	
		Medium & Serum:	See Propagation
	
	
		Growth Properties:	suspension
	
	
		Organism:	Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
	
	
		Morphology:	lymphoblast
	
	
		
	
	
		Source:	Cell Type: 18C2.8.3細胞hybridoma: B lymphocyte;
	
	
		Cellular Products:	immunoglobulin; monoclonal antibody; against NK cell target ligand on NC-37 cells
	
	
		Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
	
	
		Tumorigenic:	Yes
	
	
		Comments:	Animals were immunized with NC-37 (see ATCC CCL-214) cells.
	
	
		Spleen cells were fused with P3X63Ag8.653 myeloma cells.
	
	
		18C2.8.3細胞The antibody reacts with NC-37 cells and inhibits NK cell mediated lysis.
	
	
		The antibody also blocks lysis by catfish nonspecific cytotoxic cells (NCC) which are analogous to mammalian NK cells.
	
	
		Propagation:	ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
	
	
		Subculturing:	Medium Renewal: Every 2 to 3 days
	
	
		Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 2 X 10 exp5 and 1 X 10 exp6 cells/ml.
	
	
		Preservation:	Culture medium, 95%; DMSO, 5%
	
	
		References:	22020: Evans DL. 18C2.8.3細胞Antibodies to natural killer cell and non-specific cytotoxic cell receptor and target cell antigens. US Patent 5,194,593 dated Mar 16 1993